Abstract
Although many B-cell malignancies are sensitive to chemotherapy and radiotherapy and some may be cured, the majority relapse and prove fatal. Even at the extremes of dose escalation requiring bone marrow transplantation or peripheral blood stem cell rescue, there are resistant cells in many tumors that will ultimately lead to relapse. Immunotherapeutic approaches to the destruction of tumors have attracted interest because resistance to chemotherapy and radiotherapy probably does not confer resistance to immune-mediated killing. In addition, a highly selective attack on tumor cells might avoid the morbidity associated with more conventional approaches. Immunotherapy is not yet a standard part of the approach to malignancy because of the difficulties identifying antigens that are truly tumor specific and inducing a host response to these antigens. Epstein-Barr virus (EBV)-associated lymphomas present some interesting opportunities in this regard.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Liebowitz D, Kieff E (1993) Epstein-Barr virus. In: The Human Herpesviruses ( Roizman B, Whitley RJ, Lopez C eds), New York: Raven Press, pp. 107–172.
MacMahon EME, Glass JD, Hayward SD, Mann RB, Becker PS, Charache P, McArthur JC, Ambinder RF (1991) Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet 338: 969–973.
Ambinder RF, Browning PJ, Lorenzana I, Leventhal BG, Cosenza H, Mann RB, MacMahon EME, Medina R, Cardona V, Grufferman S, Olshan A, Levin A, Petersen EA, Blattner W, Levine PH (1993) Epstein-Barr virus and childhood Hodgkin’s disease in Honduras and the United States. Blood 81: 462–467.
Carmichael A, Jin X, Sissons P, Borysiewicz L (1993) Quantitative analysis of the human immunodeficiency virus type 1 (HlV-l)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: Differential CTL responses to HIV-1 and Epstein-Barr virus in late disease. J Exp Med 177: 249–256.
Bourgault I, Gomez A, Gomard E, Levy JP (1991) limiting-dilution analysis of the HLA restriction of anti-Epstein-Barr virus-specific cytolytic T lymphöcytes. Clin Exp Immunol 84: 501–507.
Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH, Castro-Malaspina H, Childs BH, Gillio AP, Small TN, Young JW, Keman NA, O’Reilly RJ (1994) Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 33: 1185–1191.
Khanna R, Burrows SR, Kurilla MG, Jacob CA, Misko IS, Sculley TB, Kieff E, Moss DJ (1992) Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: Implications for vaccine development. J Exp Med 176: 169–176.
Murray RJ, Kurilla MG, Brooks JM, Thomas WA, Rowe M, Kieff E, Rickinson AB (1992) Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): Implications for the immune control of EBV-positive malignancies. J Exp Med 176: 157–168.
Bird A (1992) The essentials of DNA methylation. Cell 70: 5–8.
Masucci MG, Contreras-Salazar B, Ragnar E, Falk K, Minarovits J, Ernberg I, Klein G (1989) 5-Azacytidine up regulates the expression of Epstein-Barr virus nuclear antigen 2 (EBNA-2) through EBNA-6 and latent membrane protein in the Burkitt’s lymphoma line Rael. J Virol 63: 3135–3141.
Qu L, Rowe DT (1992) Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes. J Virol 66: 3715–3724.
Chabner BA (1990) Cytidine analogues. In: Cancer chemotherapy: principles and practice ( Chabner BA, Collins JM eds), Philadelphia: Lippincott. pp. 154–179.
Humphries RK, Dover G, Young NS, Moore JG, Charache S, Ley T, Nienhuis AW (1985) 5-Azacytidine acts directly on both eiythroid precursors and progenitors to increase production of fetal hemoglobin. J Clin Invest
Dover GJ, Charache S, Boyer SH, Vogelsang G, Moyer M (1985) 5-Azacytidine increases HbF production and reduces anemia in sickle cell disease: dose-response analysis of subcutaneous and oral dosage regimens. Blood 66: 527–32.
Weber J, Saigaller D, Samid S, Johnson B, Herlyn M, Lassam N, Treisman J, Rosenberg SA (1994) Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2’deoxycytidine. Can Res 54: 1766–71.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Robertson, K.D., Barletta, J., Samid, D., Ambinder, R.F. (1995). Pharmacologic Activation of Expression of Immunodominant Viral Antigens: A New Strategy for the Treatment of Epstein-Barr-Virus-Associated Malignancies. In: Potter, M., Melchers, F. (eds) Mechanisms in B-Cell Neoplasia 1994. Current Topics in Microbiology and Immunology, vol 194. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-79275-5_18
Download citation
DOI: https://doi.org/10.1007/978-3-642-79275-5_18
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-79277-9
Online ISBN: 978-3-642-79275-5
eBook Packages: Springer Book Archive